Emisphere Technologies Elects Tim Rothwell to Its Board
EMIS | Quote | Chart | News | PowerRating -- Emisphere Technologies, Inc. has announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company's Board of Directors effective immediately.
Rothwell's appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain other business endeavors.
Commenting on the news, Michael V. Novinski, President and Chief Executive Officer of Emisphere, said, "We are very pleased to welcome Tim to our Board. With more than 35 years of pharmaceutical experience, his outstanding reputation, proven leadership capabilities and knowledge of research and development and commercial operations, will be invaluable as we are beginning to bring our first product - oral Eligen B12 (100 mcg) - to market, and as we advance key compounds in our pipeline going forward."
From February 2007 to March 2009, Rothwell served as Chairman of Sanofi-aventis U.S. From September 2004 to February 2007, Rothwell was President and Chief Executive Officer of the company, overseeing all domestic commercial operations as well as coordination of Industrial Affairs and Research and Development activities.
From May 2003 to September 2004, Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-aventis U.S. in 2004. Prior to that, from June 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company's Global Prescription Business.
Emisphere is a biopharmaceutical company that focuses on the improved delivery of therapeutic molecules or nutritional supplements using its proprietary Eligen Technology.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on (EMIS) EMIS. (EMIS) has Short Term PowerRatings at TradingMarkets. Details on (EMIS) Short Term PowerRatings is available at This Link.
- Emisphere to Present at 12th Annual BIO CEO & Investor Conference - 02/02/10
- Novo Nordisk initiates Phase I study of diabetes - 01/15/10
- Novo Nordisk Starts Phase I Trial with Long-Acting Oral GLP-1 Analogue - 01/13/10
- Emisphere Technologies Inc (EMIS.OB) Corporate Event Announcement Notice - 01/12/10
- Green Opening For Stocks - 05/14/02
- More News >>


